Gennex Laboratories
add_icon

Gennex Laboratories

13.49
-0.54
(-3.85%)
Market Cap
₹- Cr
PE Ratio
-
Volume
4,36,471.00
Day High - Low
₹14.40 - ₹13.40
52W High-Low
₹19.20 - ₹10.84
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
- Cr
EPS
-
PB Ratio
-
Book Value
8.79
EBITDA
-
Dividend Yield
- %
Industry
Healthcare
ROE Growth %
-
Debt to Equity
-
Forecast For
Actual

Company News

View All News
Caret
neutral
Gennex Laboratories Reports Strong Growth in Quarterly Results with Revenue Rising to Rs. 2,928 LakhsNov 14, 2025
Gennex Laboratories Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2025, showing consolidated revenue of Rs. 2,928.04 lakhs compared to Rs. 2,468.59 lakhs in the previous year quarter. The pharmaceutical company, which operates in bulk drugs manufacturing including Guaifenesin and Methocarbamol with international operations, reported consolidated net profit of Rs. 551.15 lakhs for the quarter with earnings per share of Rs. 0.207.
positive
Gennex Laboratories reported standalone revenue of Rs 2,564 lacs for the quarter ended June 30, 2025, up from Rs 2,133.40 lacs in the same quarter last year. Net profit increased significantly to Rs 414.95 lacs compared to Rs 416.60 lacs in the previous year quarter. On a consolidated basis, revenue reached Rs 3,417.75 lacs versus Rs 2,832.18 lacs in the prior year quarter, while net profit was Rs 501.64 lacs compared to Rs 465.84 lacs. The company's paid-up equity share capital increased to Rs 2,314.48 lacs from Rs 2,274.48 lacs. Basic earnings per share stood at Rs 0.179 for standalone and Rs 0.217 for consolidated results. The board meeting was held on August 14, 2025, where directors approved the unaudited financial statements along with limited review reports from statutory auditors.
positive
Gennex Laboratories Unit Receives Approval for Additional Product ManufacturingOct 28, 2024
A unit of Gennex Laboratories has obtained approval from the Andhra Pradesh government to manufacture additional products. This development suggests an expansion of the company's production capabilities and potential growth in its product portfolio.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
790.15
-
#1 -
-
-
-
-
34.61
699.20
-
#1 -
-
-
-
-
43.29
64.57
-
#1 -
-
-
-
-
21.03
554.80
-
#1 -
-
-
-
-
37.85
28,850.00
-
#1 -
-
-
-
-
39.24
42.05
-
#1 -
-
-
-
-
41.15
54.60
-
#1 -
-
-
-
-
42.72
5,001.00
-
#1 -
-
-
-
-
43.40
414.10
-
#1 -
-
-
-
-
43.97
26.95
-
#1 -
-
-
-
-
41.68
Growth Rate
Revenue Growth
-
Net Income Growth
-
Cash Flow Change
-
ROE
-
ROCE
-
EBITDA Margin (Avg.)
-

Quarterly Financial Results

Quarterly Financials
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
8
11
12
14
10
11
15
21
16
14
15
12
13
15
15
16
10
14
17
20
14
19
14
19
17
18
19
34
31
32
38
44
37
39
Expenses
7
10
11
14
9
10
14
19
15
13
14
11
12
14
14
14
9
12
15
19
13
18
13
17
11
12
17
29
24
26
33
39
29
32
EBITDA
1
1
1
1
1
1
1
2
2
1
1
1
1
2
2
3
2
2
1
1
1
1
1
1
5
5
3
4
7
6
5
6
7
8
Operating Profit %
9 %
8 %
7 %
-1 %
8 %
7 %
8 %
7 %
8 %
7 %
4 %
5 %
6 %
10 %
11 %
16 %
16 %
13 %
7 %
4 %
6 %
7 %
8 %
7 %
31 %
29 %
13 %
13 %
15 %
18 %
13 %
5 %
15 %
15 %
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
1
1
1
1
1
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
0
1
1
1
1
Profit Before Tax
0
0
1
0
1
1
1
1
1
1
0
0
1
1
2
2
1
2
1
1
1
1
2
3
4
4
4
5
6
6
6
4
6
6
Tax
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
1
1
1
Net Profit
0
0
0
-0
1
1
1
0
1
1
0
0
0
1
1
2
1
1
1
1
1
1
1
2
3
3
3
5
5
5
5
3
5
6
EPS in ₹
0.03
0.03
0.02
-0.02
0.03
0.04
0.07
0.02
0.06
0.04
0.02
0.02
0.03
0.07
0.10
0.15
0.08
0.09
0.06
0.10
0.06
0.08
0.07
0.19
0.16
0.16
0.16
0.16
0.19
0.21
0.22
0.14
0.22
0.21

Balance Sheet

Balance Sheet
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
49
51
52
57
59
68
132
230
256
Fixed Assets
16
16
16
15
14
14
74
56
60
Current Assets
26
28
29
35
38
47
49
162
181
Capital Work in Progress
0
0
0
0
0
0
0
2
5
Investments
7
7
7
7
7
7
0
0
0
Other Assets
27
28
29
35
38
48
59
172
191
Total Liabilities
49
51
52
57
59
68
132
230
256
Current Liabilities
17
18
17
21
19
24
30
40
45
Non Current Liabilities
1
1
1
0
0
0
16
13
17
Total Equity
31
32
34
36
40
44
87
177
195
Reserve & Surplus
18
19
21
23
27
31
62
142
158
Share Capital
13
13
13
13
13
13
18
23
23

Cash Flow

Cash Flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
-0
0
2
-2
0
8
6
46
-5
Investing Activities
-1
-1
-1
-0
0
-3
-38
19
1
Operating Activities
-0
3
2
-2
-1
12
24
-47
-11
Financing Activities
1
-2
1
-0
2
-2
21
74
5

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Aug 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Feb 2024
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Jul 2025
Sept 2025
Promoter
22.05 %
22.05 %
22.05 %
22.05 %
22.05 %
22.05 %
23.38 %
23.38 %
23.38 %
23.38 %
23.38 %
23.60 %
23.60 %
18.42 %
18.42 %
18.42 %
18.42 %
18.42 %
18.42 %
19.83 %
23.62 %
23.62 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
63.16 %
70.52 %
74.55 %
73.70 %
75.16 %
74.50 %
61.37 %
63.41 %
63.41 %
63.27 %
60.60 %
58.05 %
60.22 %
58.81 %
60.42 %
61.74 %
59.00 %
60.53 %
62.19 %
61.90 %
58.97 %
59.34 %
Others
14.79 %
7.43 %
3.40 %
4.25 %
2.79 %
3.45 %
15.25 %
13.21 %
13.21 %
13.35 %
16.02 %
18.34 %
16.17 %
22.78 %
21.16 %
19.85 %
22.59 %
21.05 %
19.39 %
18.28 %
17.41 %
17.04 %
No of Share Holders
20,806
36,243
46,380
50,052
56,689
57,877
57,603
59,172
58,248
55,609
52,981
50,988
69,723
69,750
83,996
87,820
90,236
92,506
92,326
91,183
91,183
90,320

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
22 Jul 2022 RIGHTS Rights
1:2
21 Jul 2022 6.66 6.82
30 Dec 2023 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
30 Dec 2023 16.10 16.81
30 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Sept 2024 18.56 23.62
14 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Nov 2024 20.41 19.21
14 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Feb 2025 14.47 13.50
30 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 May 2025 13.11 13.79
14 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Aug 2025 13.00 12.45
30 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Sept 2025 11.48 11.43
14 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Nov 2025 15.46 15.67

Announcements

Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 17, 2025
Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025Nov 14, 2025
Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025Nov 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 06, 2025
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30 2025Nov 04, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 13, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportOct 01, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2025
Closure of Trading WindowSep 23, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 08, 2025
Reg. 34 (1) Annual Report.Sep 08, 2025
Intimation Of Book Closure For AGMSep 04, 2025
Board Meeting Outcome for For Meeting Held On 04Th September 2025 For Approval Of Board Reports And AGM Related AgendaSep 04, 2025
Board Meeting Intimation for Fixing Date Time And Venue Of 40Th AGM Of The CompanyAug 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 18, 2025
Unaudited Financial Results For The Quarter Ended June 30 2025Aug 14, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Of Gennex Laboratories Limited Held On August 14 2025 For Unaudited Financial Results Of First Quarter Ended June 30 2025 Aug 14, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 07, 2025
Approval Of Products From Drugs Control Administration Government Of Andhra Pradesh For Our Subsidiary Company Deccan Remedies LimitedJul 28, 2025
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30 2025Jul 28, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 24, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Board Meeting Outcome for Board Meeting Held On July 08 2025 For Conversion Of 55 Lakhs Warrants Into Equity SharesJul 08, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 07, 2025
Board Meeting Outcome for Board Meeting Held On July 04 2025 For Conversion Of 60 Lacs Warrants Into Equity SharesJul 04, 2025
Closure of Trading WindowJun 23, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Of Gennex Laboratories Limited Held On June 04 2025 For Conversion Of Warrants Into Equity SharesJun 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 02, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
Appointment Of Mr. Sandeep Kumar Daga As Additional (Non-Executive Non Independent) Director Of The CompanyMay 30, 2025
Announcement under Regulation 30 (LODR)-Resignation of DirectorMay 30, 2025
Audited Financial Results For The Year Ended March 31 2025May 30, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On May 30 2025 For Audited Financial Result For The Quarter And Year Ending March 31 2025May 30, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 22, 2025
Approval Of Additional Products From Drugs Control Administration Government Of Andhra Pradesh For Our Subsidiary Company Deccan Remedies LimitedMay 22, 2025
Board Meeting Intimation for For Consideration And Approval Of Audited Financial Results (Standalone And Consolidated) For The Quarter And Year Ended March 31 2025May 20, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 22, 2025
Closure of Trading WindowMar 26, 2025
Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.Mar 24, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Mar 24, 2025
Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.Mar 20, 2025
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011Mar 20, 2025
Integrated Filing (Financial)Mar 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 17, 2025
Unaudited Financial Results For Quarter And Nine Months Ended December 31 2024Feb 14, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Of Gennex Laboratories LimitedFeb 14, 2025
Statement Of Deviation Or Variation In The Use Of Proceeds Pursuant To Regulations 32 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations. - Scrip Code: 531739/GENNEX Feb 14, 2025
Announcement under Regulation 30 (LODR)-Resignation of DirectorFeb 14, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 10, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 10, 2025

Technical Indicators